Table I.
Clinical data of patients†
| Group | Duration of disease1 (mean ± SD yrs) | UPDRS‐Score2 | FDOPA‐uptake (Kc)3 | |||||
|---|---|---|---|---|---|---|---|---|
| Total | I | II | III | IV | Putamen | Nc.caud. | ||
| (mean ± SD) | (mean ± SD) | |||||||
| All patients (N = 12) | 7.7 ± 4.1 | 36.7 ± 19.3 | 2.6 ± 1.7 | 15.7 ± 7.6 | 16.5 ± 6.0 | 6.3 ± 5.4 | 0. 00437 ± 0. 00188 | 0. 00729 ± 0. 00178 |
| Subgroup A (N = 5) | 4.6 ± 2.2 | 19.0 ± 10.5 | 1.6 ± 1.7 | 9.8 ± 3.8 | 15.6 ± 4.7 | 2.6 ± 5.0 | 0. 00544 ± 0. 00243 | 0. 00905 ± 0. 00072 |
| Subgroup B (N = 7) | 9.9* ± 4.4 | 49.3* ± 12.7 | 3.3 ± 1.4 | 19.9* ± 6.9 | 17.1 ± 7.1 | 19.0* ± 4.9 | 0. 00366 ± 0. 00105 | 0. 00639* ± 0. 00104 |
| Normals (N = 12) | 0. 00967 ± 0. 00078 | 0. 01135 ± 0. 00115 | ||||||
†, *
Comparison of subgroups A an B, *indicates significant differences in the unpaired, two‐tailed t‐test.
1
Duration of disease: P < .05.
2
Unified Parkinson's disease rating scale, total: P < .01; 4 components: (I) Mentation, behavior and mood; (II) Activities of daily living: P < .05; (III) Motor examination; (IV) Complications of therapy: P < .05.
3
FDOPA‐uptake in the caudate nucleus: P < .001.